trending Market Intelligence /marketintelligence/en/news-insights/trending/q5heJRztMl8435-jx20hNQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Medica Clinical Nord swings to profit in Q2

An interview with Antony Jenkins, Founder & Executive Chairman, 10x Future Technologies

An interview with Nicolas Veron, Economist, Senior Fellow at Bruegel

An interview with Dan Frumkin, CEO, Metro Bank

Investment Banking: The Outlook, Market Share and Competitive Advantage

Medica Clinical Nord swings to profit in Q2

MedicaNatumin AB (publ) said its second-quarter normalized net income came to 1.4 million kronor, compared with a loss of 500,000 kronor in the year-earlier period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin climbed to 4.2% from negative 2.3% in the year-earlier period.

Total revenue rose 43.9% on an annual basis to 30.8 million kronor from 21.4 million kronor, and total operating expenses grew 29.5% from the prior-year period to 28.5 million kronor from 22.0 million kronor.

Reported net income came to 2.4 million kronor, or 1 öre per share, compared to a loss of 700,000 kronor, or a loss of 0 öre per share, in the prior-year period.

As of Sept. 1, US$1 was equivalent to 8.57 Swedish kronor.